0

Back to Society of Hematopathology Quarterly Case Winter 2016: Primary myelofibrosis with an unusual MPL mutation: Integrating molecular testing into the diagnosis and prognosis of BCR-ABL1 negative myeloproliferative neoplasms.

Society of Hematopathology Quarterly Case Winter 2016: Primary myelofibrosis with an unusual MPL mutation: Integrating molecular testing into the diagnosis and prognosis of BCR-ABL1 negative myeloproliferative neoplasms.

In the past ten years, the genomic landscape of BCR-ABL1 negative myeloproliferative neoplasms has changed considerably.  Driver mutations in JAK2, MPL, and most recently, somatic mutations of CALR, have been identified in approximately 90% of patients with primary myelofibrosis (PMF) and essential thrombocythemia (ET).  In both ET and PMF, particular driver mutations appear to be associated with distinct clinical/pathologic findings and appear to be prognostically significant. Patients with PMF lacking JAK2, MPL, and CALR mutations have markedly worse outcomes than those with CALR mutations. Accordingly, diagnosis of BCR-ABL1 negative myeloproliferative neoplasms now needs to have a thorough accompanying molecular analysis to appropriately risk stratify patients.  This is a case of primary myelofibrosis with an unusual MPL mutation. The course also presents guidelines for interpretation of these and similar data of diagnostic and prognostic value.
  • List Price: $0.00 USD

Item Details:

Intended Audience: Pathologists, Residents, and Laboratory Professionals

Upon completion of this activity, you will be able to:

  contrast the morphologic characteristics of polycythemia vera, essential thrombocythemia, and primary myelofibrosis.

  describe the characteristic driver...

Back to Society of Hematopathology Quarterly Case Winter 2016: Primary myelofibrosis with an unusual MPL mutation: Integrating molecular testing into the diagnosis and prognosis of BCR-ABL1 negative myeloproliferative neoplasms.
View More